Vocabria

FC tab: In combination w/ rilpivirine tab for short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on stable antiretroviral regimen w/o present or past evidence of viral resistance to & no prior virological failure w/ agents of NNRTI & integrase inhibitor (INI) class as: oral lead-in to assess tolerability prior to administration of long-acting Vocabria inj; oral therapy for adults who will miss planned dosing w/ Vocabria inj. Susp for inj: In combination w/ rilpivirine inj for short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on stable antiretroviral regimen w/o present or past evidence of viral resistance to & no prior virological failure w/ agents of NNRTI & INI class.

FC tab Oral lead-in Cabotegravir 30 mg + rilpivirine 25 mg once daily for mth 1 (at least 28 days) followed by inj initiation. Susp for inj IM Mthly dosing Initiation inj: Cabotegravir 600 mg + rilpivirine 900 mg on the last day of current antiretroviral therapy (ART) or oral lead-in if used. Continuation inj: Cabotegravir 400 mg + rilpivirine 600 mg 1 mth after initiation inj & mthly onwards. May be given inj up to 7 days before or after the date of mthly dosing schedule. Every 2 mth dosing Initiation inj: Cabotegravir 600 mg + rilpivirine 900 mg on the last day of current ART or oral lead-in if used & 1 mth later. Continuation inj: Cabotegravir 600 mg + rilpivirine 900 mg 2 mth after last initiation inj & every 2 mth onwards. May be given inj up to 7 days before or after the date of every 2 mth dosing schedule. Switching from mthly to every 2 mth dosing Single 600 mg inj 1 mth after the last 400 mg continuation inj & then 600 mg every 2 mth thereafter. Switching from every 2 mth to mthly dosing Single 400 mg inj 2 mth after the last 600 mg continuation inj & then 400 mg mthly thereafter.

FC tab: May be taken with or without food: Take w/ meal if Vocabria tab is taken at the same time as rilpivirine tab.

Hypersensitivity. Concomitant use w/ rifampicin, rifapentine, phenytoin, phenobarb, carbamazepine & oxcarbazepine.

Antivirals

J05AJ04 - cabotegravir ; Belongs to the class of integrase inhibitors. Used as direct acting antiviral in the systemic treatment of viral infections.

POM